Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

摘要

Abstract The present invention relates to compounds of Formula (i) or (ii), or a pharmaceutically acceptable salt, ester, or 5 prodrug, thereof: formula (I), formula (II): which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and 10 are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCF infection. The invention also relates to methods of treating an HCV infection in a 15 subject by administering a pharmaceutical composition comprising the compounds of the present invention. C:NrPortbl/GHMatters/ROSG21 992211. DOC 19102110